Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Dementia

Dementia

Subtypes of Dementia

Alzheimer's Disease 124 Dementia with Lewy bodies 7 Vascular Dementia 7 Huntington's Disease 5 Frontotemporal dementia 4 Amnestic dementia 1 Lewy body disorders 1 Young-onset dementia 1 Dementia epileptica 0

172 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Dementia

202 trials tracked for Dementia: 16 in phase 3 or 4 and 6 with published results. The most-cited published study has 71 citations.

202Trials tracked
16Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 8 Phase 3 8 Phase 2 15 Phase 1 5 Other / NA 166
  1. Phase 3 The Healthy Patterns Sleep Study Completed · 71 cited
  2. Phase 4 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed · 36 cited
  3. Phase 3 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Completed · 29 cited
  4. Phase 3 Preventing Aggression in Veterans With Dementia Completed · 28 cited
  5. Phase 4 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation Completed · 15 cited
  6. Phase 4 Monitoring Anti-Dementia Drugs by Serum Levels Completed
Show 44 more trials
  1. Phase 4 Corticolimbic Degeneration and Treatment of Dementia Completed
  2. Phase 4 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed
  3. Phase 4 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed
  4. Phase 4 Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study Completed
  5. Phase 4 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed
  6. Phase 3 Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia Completed
  7. Phase 3 Cholinesterase Inhibitor Discontinuation Completed
  8. Phase 3 Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type Completed
  9. Phase 3 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II) Completed
  10. Phase 3 Ginkgo Biloba Prevention Trial in Older Individuals Completed
  11. Phase 2 A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD Completed
  12. Phase 2 A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease Completed
  13. Phase 2 iCare Stress Management e-Training for Dementia Family Caregivers Completed
  14. Phase 2 A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease Completed
  15. Phase 2 Development of NIC5-15 in the Treatment of Alzheimer's Disease Completed
  16. Phase 2 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed
  17. Phase 2 A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) Completed
  18. Phase 2 Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease Completed
  19. Phase 2 Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease Completed
  20. Phase 2 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed
  21. Phase 2 A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment Completed
  22. Phase 2 Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Completed
  23. Phase 2 LifeZig Personalized Reminiscence Video With Slideshows and Music for Individuals With Alzheimer's and Dementia Completed
  24. Phase 2 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) Completed
  25. Phase 2 A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) Completed
  26. Phase 1 Home Safety Clinical Trial for Alzheimer's Disease Completed
  27. Phase 1 The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression Completed
  28. Phase 1 Encouraging Cognitive Screenings at African American Churches Completed
  29. Phase 1 The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women Completed
  30. Phase 1 Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices Completed
  31. N/A Mobile Tablet Education to Advance Caregiver Health Completed
  32. N/A Savvy System Project Completed
  33. N/A SimpleC Wellness Platform With Social Robot Interaction Completed
  34. N/A Movement Intervention for Memory Enhancement Completed
  35. N/A Moving Together: An Online Group Movement Program for People Living With Memory Loss and Caregivers Completed
  36. N/A Program of Intensive Support in Emergency Departments for Care Partners of Cognitively Impaired Patients Completed
  37. N/A Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia Completed
  38. N/A Can Value Champions Reduce Inappropriate Prescribing for People With Dementia? Completed
  39. N/A User-Led Meaningful Activity and Early-Stage Dementia Completed
  40. N/A Aggression Prevention Training for Caregivers of Persons With Dementia (APT) Completed
  41. N/A Delivery Models of Caregiver Support and Education Completed
  42. N/A Music Based Caregiving in Patients With Pain and Dementia Completed
  43. N/A Pragmatic Trial of Video Education in Nursing Homes Completed
  44. N/A A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research Completed

Showing the 50 most-cited and recently-updated of 202 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Dementia: what the trials found

New evidence indicates that BXCL501 is associated with a reduction in the PEC Total Score for the first episode of agitation (p < 0.05) 2. Additionally, Dabigatran Etexilate showed no statistically significant differences in cognitive decline based on ADAS and DAD scales, stroke/TIA incidence, or MMSE scores 1.

Nuedexta (DM 20 mg/Q 10 mg) significantly reduced CNS-LS scores at both day 30 and day 90 (p < 0.0001), with mean reductions of approximately 7.6 to 8.5 15. It also demonstrated a significant reduction in the mean number of pseudobulbar affect episodes per week (p < 0.0001) 15.

Methylphenidate was associated with significantly higher Apathy Evaluation Scale scores at 12 weeks (p < 0.05) and significantly higher MMSE scores compared to placebo (p = 0.01) 19. Escitalopram showed a significant difference in the number of participants with recurrence of major depression (p = 0.05) 21.

Donepezil was evaluated for changes in Clinical Global Impression, Geriatric Depression Scale symptoms, and Disability Assessment for Dementia scores 16. Memantine was studied regarding the rate of change of hippocampal volume slope, though results did not reach statistical significance (p = 0.095; p = 0.066) 17.

Galantamine was evaluated in relation to Quality of Life Assessment for Caregivers and Patients with Alzheimer's Disease across baseline, week 8, and week 24 20.

Recent results — preliminary, needs further review

  • WeCareToFeedDysphagia web tool: Reported mean care partner burden (41.3 vs 42.8) and quality of life (57.7 vs 52.7) at 3 months, with a 21% engagement rate 3.
  • Cognitive Stimulation Therapy: Referral resulted in significant differences in cognitive impairment (p < 0.05), though acceptance rates were low (42% vs 5%) and completion rates were also limited (16% vs 9% vs 7%) 4.
  • Comprehensive acupuncture therapy (CAT): Reported varied changes across MMSE, Modified Bathel Index, and Visual Analogue Scale scores 8.
  • MEMORI Corps program: Showed a difference in neuropsychiatric symptoms as assessed by NPI score (3.35 vs 0.47) 9.

For the clinician treating this condition

  • Nuedexta is effective for reducing CNS-LS scores and the frequency of pseudobulbar affect episodes 15.
  • Methylphenidate shows significant improvements in MMSE scores and apathy levels at 12 weeks 19.
  • Escitalopram was associated with a lower number of recurrences of major depression 21.

AI synthesis of 12 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Elevated neutrophil-to-lymphocyte ratio correlates with greater cerebral small vessel disease burden and white matter hyperintensities
Neurology Meta-analysis
Elevated neutrophil-to-lymphocyte ratio correlates with greater cerebral small vessel disease burden and white matter hyperintensities High Neutrophil Levels Linked to Brain Small Vessel Damage
This systematic review and meta-analysis of 62,961 patients found that elevated neutrophil-to-lymphocyte ratio (NLR) is associated with the …
A large analysis finds that higher neutrophil-to-lymphocyte ratios are linked to more severe damage in the brain's small blood vessels.
Frontiers Jul 31, 2026
Pain assessment guidelines for cognitively impaired older adults lack practical detail
Anesthesiology & Pain Medicine Sys. Review
Pain assessment guidelines for cognitively impaired older adults lack practical detail Pain guidelines for dementia patients lack practical advice
This scoping review mapped pain assessment guidelines for hospitalized older adults with cognitive impairment. No Australian guidelines were…
A review finds most pain assessment guidelines for older adults with dementia offer little practical help for hospital staff.
Frontiers Jul 29, 2026
Network meta-analysis protocol aims to rank structured exercise interventions for fall prevention in dementia
Rheumatology Meta-analysis
Network meta-analysis protocol aims to rank structured exercise interventions for fall prevention in dementia Exercise Programs May Help Prevent Falls in Seniors with Dementia
This is a protocol for a systematic review and network meta-analysis regarding structured exercise interventions for older adults with mild …
A planned review aims to determine which types of structured exercise best help older adults with memory loss stay safe and avoid falling.
Frontiers Jul 24, 2026
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease
Neurology Meta-analysis
Sedative-hypnotic use associated with OR 1.29 for incident Alzheimer's Disease Meta-analysis links sedative-hypnotic drug use to higher Alzheimer risk
This meta-analysis of observational cohort and nested case-control studies involving 721,354 adults without baseline dementia found that sed…
A large study suggests a link between the use of common sleep medications like benzodiazepines and an increased risk of developing Alzheimer…
Jul 22, 2026
Bibliometric analysis identifies growing research trends and key hubs for short-chain fatty acids in cognitive impairment
Neurology Sys. Review
Bibliometric analysis identifies growing research trends and key hubs for short-chain fatty acids in cognitive impairment Mapping the Growing Research on Gut Health and Memory Loss Diseases
This systematic review provides a bibliometric analysis of 425 WoSCC and 514 Scopus records regarding short-chain fatty acids (SCFAs) and co…
Scientists are tracking how gut-related compounds might help brain health. This review maps out years of research into these important links…
Frontiers Jul 19, 2026
Multidomain lifestyle interventions provide small but statistically significant benefits for global cognition scores
Neurology Meta-analysis
Multidomain lifestyle interventions provide small but statistically significant benefits for global cognition scores Multidomain lifestyle changes may help slow signs of dementia
This meta-analysis of randomized controlled trials involving 23209 participants found that multidomain lifestyle interventions (three or mor…
Combining multiple lifestyle habits like diet and exercise can lead to small but steady improvements in brain health for those at risk of de…
medRxiv Jul 16, 2026
Berberine identified as potential Alzheimer's treatment targeting HMGCR in astrocyte-driven model
Neurology Guideline
Berberine identified as potential Alzheimer's treatment targeting HMGCR in astrocyte-driven model New research identifies a potential target for Alzheimer's disease
This guideline presents a computational analysis identifying an autolysosome-astrocyte-associated diagnostic model for Alzheimer's disease, …
Scientists identified a specific gene as a key driver of Alzheimer's and found that the compound berberine may help target it.
Frontiers Jul 15, 2026
TBP expansion in SCA17 can cause dementia-like symptoms and requires etiological reconsideration
Neurology Sys. Review
TBP expansion in SCA17 can cause dementia-like symptoms and requires etiological reconsideration New Diagnosis for Dementia Patients with Spinocerebellar Ataxia Type 17
This case report and focused literature review describes a patient with SCA17 presenting as dementia, highlighting the need for genetic test…
A new look at dementia cases may reveal an underlying genetic condition called spinocerebellar ataxia type 17.
Frontiers Jul 13, 2026
Adaptive immune signatures and T cell infiltration characterize pathology in Alzheimer's, Parkinson's, and Lewy Body dementia
Neurology Sys. Review
Adaptive immune signatures and T cell infiltration characterize pathology in Alzheimer's, Parkinson's, and Lewy Body dementia Adaptive Immune Signatures Linked to Alzheimer's and Parkinson's Disease
This mini review synthesizes evidence regarding adaptive immune remodeling and T cell responses in neurodegenerative dementias. The authors …
New research highlights how specific immune cell activity may play a role in the progression of Alzheimer's, Parkinson's, and Lewy body deme…
Frontiers Jul 9, 2026
Angiogenic factors in biofluids show no significant difference in Alzheimer's disease
Neurology Meta-analysis
Angiogenic factors in biofluids show no significant difference in Alzheimer's disease Comparing blood markers to see if they help identify Alzheimer disease
This systematic review and meta-analysis of 18 studies found a small, nonsignificant overall effect size for angiogenic factors in biofluids…
Researchers looked at several proteins in the blood to see if they could help tell the difference between healthy people and those with Alzh…
Jul 8, 2026
Exercise training promotes adult hippocampal neurogenesis by influencing the neurochemical environment and cell cycle dynamics
Neurology Sys. Review
Exercise training promotes adult hippocampal neurogenesis by influencing the neurochemical environment and cell cycle dynamics Exercise training may help grow new neurons in the brain
This narrative review synthesizes evidence regarding exercise training and its effects on adult hippocampal neurogenesis in conditions such …
Physical exercise can trigger the growth of new neurons and stem cells, potentially offering new paths for treating brain disorders like Alz…
Frontiers Jul 7, 2026
Hormonal birth control and menopausal hormone therapy associated with greater gray matter volume
Radiology & Imaging RCT
Hormonal birth control and menopausal hormone therapy associated with greater gray matter volume Hormonal Birth Control Linked to Greater Brain Volume in Women
This observational study of 459 women found that hormonal birth control (BC) and menopausal hormone therapy (MHT) were associated with incre…
New research suggests that hormonal birth control and menopausal hormone therapy may be linked to larger brain volume and thicker cortex in …
Jul 6, 2026

Questions about Dementia

Can brain scans show how my dementia is causing my memory to fade?

Yes, brain scans can show patterns of shrinkage and damage linked to memory loss in dementia, but they are one piece of a broader diagnostic picture.

Full answer →
Are there new genetic markers for Alzheimer disease found in veteran populations?

Yes, a meta-analysis of the VA Million Veterans Program identified 17 new genetic loci in European, 4 in African, and 3 in Hispanic veteran populations for Alzheimer's disease.

Full answer →
Can taking cannabinoids help reduce agitation in severe dementia cases?

Yes, cannabinoids may reduce agitation in severe dementia, but they increase sedation risk and evidence is limited.

Full answer →
Will walking while doing a task make me move slower if I have dementia?

Yes, walking while doing a task (dual-tasking) makes people with dementia move slower and take shorter steps compared to walking without a task.

Full answer →
Do antipsychotic drugs increase the risk of death for people with dementia?

Yes, antipsychotic drugs significantly increase the risk of death for people with dementia, with a pooled hazard ratio of 1.32 in a large meta-analysis.

Full answer →
See all 5 questions about Dementia →

All Dementia Articles